Losmapimod: all 27 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)TerminatedNCT05397470Phase 3Results posted
- Losmapimod Safety and Efficacy in COVID-19TerminatedNCT04511819Phase 3Results posted
- Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)TerminatedNCT04264442Phase 2Results posted
- Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With ExtensionTerminatedNCT04004000Phase 2Results posted
- Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)CompletedNCT04003974Phase 2Results posted
- Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02299375Phase 2Results posted
- A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)CompletedNCT02145468Phase 3Results posted
- A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)CompletedNCT02000440Phase 2Results posted
- Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT01218126Phase 2Results posted
- Clinical Study to Test a New Drug to Treat Major DepressionCompletedNCT00976560Phase 2Results posted
- A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment ElevationCompletedNCT00910962Phase 2Results posted
- A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT ImagingCompletedNCT00633022Phase 2Results posted
- Relative Bioavailability and Food Effect Study of Losmapimod 15 mg TabletsCompletedNCT05002231Phase 1
- A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and MoxifloxacinCompletedNCT01756495Phase 1
- Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.CompletedNCT01541852Phase 2
- Efficacy Study in Lumbosacral RadiculopathyCompletedNCT01110057Phase 2
- PK Study of IV Formulation of GW856553CompletedNCT01039961Phase 1
- Study in Neuropathic Pain Patients With Peripheral Nerve InjuryCompletedNCT00969059Phase 2
- A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00642148Phase 2
- To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult MalesCompletedNCT00599612Phase 1
- A Study of GW856553X For the Treatment of DepressionTerminatedNCT00569062Phase 2
- A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy MenCompletedNCT00549653Phase 1
- A Study to Examine the Effect of Particle Size on Bioequivalence and BioavailabilityCompletedNCT00517543Phase 1
- Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.CompletedNCT00474864Phase 2
- A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid ArthritisCompletedNCT00393146Phase 2
- A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)CompletedNCT00392587Phase 2
- Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)CompletedNCT00256919Phase 2